Liver fibrosis and CD206+ macrophage accumulation are suppressed by anti-GM-CSF therapy
JHEP Reports2019Vol. 2(1), pp. 100062–100062
Citations Over TimeTop 10% of 2019 papers
Alfonso Tan-Garcia, Fritz Lai, Joe Yeong, Sergio Erdal Irac, Pei Ying Ng, Rasha Msallam, Jeffrey Chun Tatt Lim, Lu‐En Wai, C Tham, Su Pin Choo, Tony Kiat Hon Lim, Dan Yock Young, Roberta D’Ambrosio, Elisabetta Degasperi, Riccardo Perbellini, Evan W. Newell, Nina Le Bert, Florent Ginhoux, Antonio Bertoletti, Qingfeng Chen, Charles‐Antoine Dutertre
Abstract
Liver fibrosis is a major driver of liver disease progression. Herein, we have shown that granulocyte-macrophage colony-stimulating factor (GM-CSF) plays an important role in the development of liver fibrosis. Our findings support the use of anti-GM-CSF neutralising antibodies for the management of patients with chronic liver disease resulting from both viral and non-viral causes.
Related Papers
- → Macrophage Populations and Expression of Regulatory Inflammatory Factors in Hepatic Macrophage-depleted Rat Livers under Lipopolysaccharide (LPS) Treatment(2018)43 cited
- → The Model for End-stage Liver Disease Comes of Age(2007)38 cited
- → Drug-Induced Liver Disease and Drug Use Considerations in Liver Disease(2009)10 cited
- → Lipopolysaccharide and splenic tumoricidal macrophage activation(1994)7 cited
- Lipopolysaccharide induced hyper—and hypo—responsiveness in macrophage cell lines(2003)